title: The effect of rabeprazole on regional gastric acidity and the postprandial cardia/gastro-oesophageal junction acid layer in normal subjects: a randomized, double-blind, placebo-controlled study.
abstract: BACKGROUND
  Postprandial intragastric acidity is not uniform. Postprandial proximal gastric acid pockets have been described in the present study.
  
  
  OBJECTIVE
  To determine the effects of rabeprazole on regional intragastric acidity and proximal acid pockets.
  
  
  METHODS
  Ten normal subjects underwent two 8-day oral dosing regimens with placebo or rabeprazole 20 mg each morning in a randomized, double-blind protocol. Oesophago-gastric pH monitoring was performed on days 1 and 8.
  
  
  RESULTS
  Rabeprazole increased fasting and postprandial gastric pH to above 4 in each area of the stomach on days 1 and 8. With placebo, acid pockets were identified at the cardia/gastro-oesophageal junction in 62 and 50 of 150 pull-throughs on days 1 and 8, respectively. Acid pockets were detected postprandially 3.1 +/- 0.2-5.8 +/- 0.1 cm below the proximal border of the lower oesophageal sphincter with a mean pH drop from 4.6 +/- 0.1 to 1.5 +/- 0.1. Rabeprazole decreased the number of acid pockets to 30 and 27 on days 1 and 8, respectively. Rabeprazole also decreased their length and magnitude of the pH drop.
  
  
  CONCLUSIONS
  Rabeprazole increased intragastric pH on day 1 and 8 and maintained an elevated pH during and after meals. Postprandial acid pockets, identified in the region of the cardia/gastro-oesophageal junction area postprandially, were decreased in number, length and magnitude by rabeprazole.
authors.affiliation: Gastroenterology Section, Department of Medicine, Temple University Hospital, Philadelphia, PA 19140, USA.
authors.forename: L
authors.initials: L
authors.lastname: Vo
authors.forename: H P
authors.initials: HP
authors.lastname: Simonian
authors.forename: S
authors.initials: S
authors.lastname: Doma
authors.forename: R S
authors.initials: RS
authors.lastname: Fisher
authors.forename: H P
authors.initials: HP
authors.lastname: Parkman
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000284:Administration, Oral; D000328:Adult; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000494:pharmacology*; D002299:Cardia / Q000737:chemistry*; D004311:Double-Blind Method; D004943:Esophagogastric Junction / Q000737:chemistry*; D005260:Female; D005744:Gastric Acid / Q000502:physiology*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D009853:Omeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology*; D019518:Postprandial Period; D064750:Rabeprazole
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D064750:Rabeprazole; D009853:Omeprazole